Table 2.
MCDA validation exercise outcomes.
| Meeting Dates | RWE Proposal | Endpoint | Consensus Score * | |||
|---|---|---|---|---|---|---|
| Importance | Feasibility | Total | Priority | |||
| 18 August 2021 | Polatuzumab vedotin for relapsed/refractory diffuse large B-cell lymphoma | OS | 122 | 104 | 226 | High |
| 22 November 2021 | Dabrafenib and trametinib for BRAF V600E mutation Positive Metastatic Non-Small Cell Lung Cancer | PFS | 87 | 98 | 185 | Low |
| OS | 124 | 133 | 256 | High | ||
| TTNT | 68 | 129 | 198 | Low | ||
| DOT | n/a † | n/a † | n/a † | n/a † | ||
| 23 February 2022 | Nivolumab in relapsed/refractory classical Hodgkin’s lymphoma | OS | 105 | 115 | 220 | Medium |
| Atezolizumab in combination with Bevacizumab for unresectable/metastatic hepatocellular carcinoma | OS | 105 | 107 | 212 | Medium | |
| 23 June 2022 | Durvalumab in Combination with Platinum Etoposide for Extensive-Stage Small Cell Lung Cancer | OS | 68 | 141 | 209 | Medium |
| Nivolumab in Combination with Fluoropyrimidine and Platinum-containing Chemotherapy for Metastatic Gastric Adenocarcinoma | OS | 58 | 127 | 185 | Low | |
| 5 December 2022 | Nivolumab in Combination with Fluoropyrimidine and Platinum-containing Chemotherapy for Metastatic Gastric Adenocarcinoma ‡ | OS | 77 | 127 | 204 | Low |
Abbreviations: OS, Overall survival; PFS, Progression free survival; TTNT, Time to next treatment; DOT, Duration of treatment; n/a, not applicable. * The consensus score represents an aggregated weighted score for an individual RWE proposal ranging from 100 to 300, with a larger score indicating greater value and feasibility [Parmar et al., 2023] [13]. † Due to time constraints, research questions were not assessed. ‡ Previously reviewed in the June 2022 meeting.